Insights

Recent Acquisition CartiHeal was acquired by Smith+Nephew in late 2023 for $330 million, indicating strong market validation and potential for integration into a broader portfolio of advanced medical solutions, offering sales opportunities through existing distribution channels.

Growing Market Presence The commercial launch of the Agili-C implant in the US in July 2023 reflects the company’s focus on expanding its geographic reach and product adoption, creating opportunities to engage with hospitals, clinics, and healthcare providers adopting innovative cartilage repair technologies.

Regulatory Milestone Receiving FDA Breakthrough Therapy Approval positions CartiHeal’s products as promising solutions for unmet medical needs, enabling rapid market entry and appealing to healthcare facilities seeking cutting-edge regenerative treatments.

Funding & Revenue Potential With current revenues between $1M and $10M and recent strategic investments, there is scope for increased sales through targeted outreach to orthopedic centers and specialists involved in cartilage and osteochondral defect treatments.

Market Trends As a developer of innovative, cell-free implants for joint repair, CartiHeal is aligned with growing trends in minimally invasive and regenerative medicine, presenting opportunities to collaborate with hospitals and surgeons focused on advanced orthopedic solutions.

Similar companies to CartiHeal

CartiHeal Tech Stack

CartiHeal uses 8 technology products and services including WordPress, Cart Functionality, Google Fonts API, and more. Explore CartiHeal's tech stack below.

  • WordPress
    Content Management System
  • Cart Functionality
    E-commerce
  • Google Fonts API
    Font Scripts
  • Font Awesome
    Font Scripts
  • Twemoji
    Font Scripts
  • HSTS
    Security
  • UIKit
    UI Frameworks
  • X-Content-Type-Options
    Web & Portal Technology

Media & News

CartiHeal's Email Address Formats

CartiHeal uses at least 1 format(s):
CartiHeal Email FormatsExamplePercentage
First@cartiheal.comJohn@cartiheal.com
47%
First.Last@cartiheal.comJohn.Doe@cartiheal.com
5%
FirstL@cartiheal.comJohnD@cartiheal.com
1%
First@cartiheal.comJohn@cartiheal.com
47%

Frequently Asked Questions

What is CartiHeal's official website and social media links?

Minus sign iconPlus sign icon
CartiHeal's official website is cartiheal.com and has social profiles on LinkedInCrunchbase.

What is CartiHeal's NAICS code?

Minus sign iconPlus sign icon
CartiHeal's NAICS code is 3391 - Medical Equipment and Supplies Manufacturing.

How many employees does CartiHeal have currently?

Minus sign iconPlus sign icon
As of December 2025, CartiHeal has approximately 51 employees across 2 continents, including AsiaNorth America. Key team members include Director Of Sales: S. H.Administrative Coordinator: A. A.Elementary Special Education Teacher: A. P.. Explore CartiHeal's employee directory with LeadIQ.

What industry does CartiHeal belong to?

Minus sign iconPlus sign icon
CartiHeal operates in the Medical Equipment Manufacturing industry.

What technology does CartiHeal use?

Minus sign iconPlus sign icon
CartiHeal's tech stack includes WordPressCart FunctionalityGoogle Fonts APIFont AwesomeTwemojiHSTSUIKitX-Content-Type-Options.

What is CartiHeal's email format?

Minus sign iconPlus sign icon
CartiHeal's email format typically follows the pattern of First@cartiheal.com. Find more CartiHeal email formats with LeadIQ.

How much funding has CartiHeal raised to date?

Minus sign iconPlus sign icon
As of December 2025, CartiHeal has raised $15M in funding. The last funding round occurred on Jul 16, 2020 for $15M.

When was CartiHeal founded?

Minus sign iconPlus sign icon
CartiHeal was founded in 2009.

CartiHeal

Medical Equipment ManufacturingCentral District, Israel51-200 Employees

CartiHeal, a privately-held medical device company with headquarters in Israel, develops proprietary implants for the treatment of cartilage and osteochondral defects in traumatic and osteoarthritic joints.
CartiHeal’s cell-free, off-the-shelf implant is CE marked for use in cartilage and osteochondral defects. Agili-C has been implanted in over 400 patients with cartilage lesions in the knee, ankle and great toe in a series of trials conducted in leading centers in Europe and Israel. In these trials, the implant was used to treat a broad spectrum of cartilage lesions, from single focal lesions to multiple and large defects in patients suffering from osteoarthritis.
In the United States the Agili-C implant is not available for sale - it is an investigational device limited for use in the IDE study.

Section iconCompany Overview

NAICS Code
3391 - Medical Equipment and Supplies Manufacturing
Founded
2009
Employees
51-200

Section iconFunding & Financials

  • $15M

    CartiHeal has raised a total of $15M of funding over 8 rounds. Their latest funding round was raised on Jul 16, 2020 in the amount of $15M.

  • $1M$10M

    CartiHeal's revenue is estimated to be in the range of $1M$10M

Section iconFunding & Financials

  • $15M

    CartiHeal has raised a total of $15M of funding over 8 rounds. Their latest funding round was raised on Jul 16, 2020 in the amount of $15M.

  • $1M$10M

    CartiHeal's revenue is estimated to be in the range of $1M$10M

Ready to create more pipeline?

Get a demo and discover why thousands of SDR and Sales teams trust
LeadIQ to help them build pipeline confidently.

© LeadIQ, Inc. All rights reserved.